PMID- 25070830 OWN - NLM STAT- MEDLINE DCOM- 20150402 LR - 20140729 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 18 IP - 15 DP - 2014 TI - The anti-inflammatory effects of 1,1 dimethyl-4-phenylpiperazinium (DMPP) compared to dexamethasone in a guinea pig model of ovalbumin induced asthma. PG - 2228-36 LID - 7668 [pii] AB - BACKGROUND AND AIM: Inflammatory cells involved in the pathophysiology of asthma express nicotinic receptor. Therefore 1,1 dimethyl(-4-)phenylpiperazinium (DMPP) in two doses were compared to dexamethasone in asthmatic guinea pigs. MATERIALS AND METHODS: Six groups were included; Normal control and five asthmatic (OVA-sensitized and challenged) groups; which were treated for 10 days as follows: two vehicles, dexamethasone (DEXA, 1 mg/kg) and DMPP (0.4 and 0.8 mg/kg) groups. Pulmonary functions and airway hyper-responsiveness were assessed. Leukocytic count, tumor necrosis factor-alpha (TNFalpha), interleukin-6 (IL-6) and immunoglobulin E (IgE) were measured in both blood and bronchoalveolar lavage fluid (BALF). Histopathological examination of the lung tissues was conducted. RESULTS: Asthmatic untreated animals exhibited significant increase in early and late airway resistance (RxV) and airway hyper-responsiveness, with reduction in tidal volume. Both blood and BALF showed significant increase in total leukocytic count (TLC), eosinophils, lymphocytes, monocytes, TNF-alpha, IL-6 and IgE with significant decrease in neutrophils. Airway inflammatory cell infiltration and smooth muscle thickness significantly increased. DMPP 0.4 mg/kg significantly decreased late phase RXV, TLC, BALF lymphocytes, TNF-alpha, smooth muscle thickness and increased neutrophils in BALF over both DEXA and DMPP 0.8 mg/kg. Moreover, DMPP 0.4 mg/kg significantly decreased IL-6 and BALF eosinophils than DMPP 0.8 mg/kg and decreased serum IgE and parenchymal inflammatory infiltration than DEXA. CONCLUSIONS: Low dose DMPP has more anti-inflammatory effect than a high dose in most parameters and sometimes than dexamethasone. Cholinergic anti-inflammatory pathway may therefore represent a potential drug target for allergic asthma. The dose related effect of DMPP and the mechanism underlying this effect require further evaluation. FAU - Murad, H A AU - Murad HA AD - Department of Pharmacology, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia. helmy_amany@yahoo.com. FAU - Hasanin, A H AU - Hasanin AH LA - eng PT - Journal Article PL - Italy TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 RN - 0 (Anti-Asthmatic Agents) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Interleukin-6) RN - 0 (Tumor Necrosis Factor-alpha) RN - 37341-29-0 (Immunoglobulin E) RN - 54-77-3 (Dimethylphenylpiperazinium Iodide) RN - 7S5I7G3JQL (Dexamethasone) RN - 9006-59-1 (Ovalbumin) SB - IM MH - Animals MH - Anti-Asthmatic Agents/pharmacology MH - Anti-Inflammatory Agents/*pharmacology MH - Asthma/*chemically induced/*drug therapy/metabolism MH - Bronchoalveolar Lavage Fluid/chemistry MH - Dexamethasone/*pharmacology MH - Dimethylphenylpiperazinium Iodide/*pharmacology MH - Disease Models, Animal MH - Eosinophils/drug effects/metabolism MH - Guinea Pigs MH - Immunoglobulin E/metabolism MH - Interleukin-6/metabolism MH - Leukocyte Count/methods MH - Lung/drug effects/metabolism MH - Lymphocytes/drug effects/metabolism MH - Male MH - Monocytes/drug effects/metabolism MH - Muscle, Smooth/drug effects/metabolism MH - Neutrophils/drug effects/metabolism MH - Ovalbumin/*adverse effects MH - Tumor Necrosis Factor-alpha/metabolism EDAT- 2014/07/30 06:00 MHDA- 2015/04/04 06:00 CRDT- 2014/07/30 06:00 PHST- 2014/07/30 06:00 [entrez] PHST- 2014/07/30 06:00 [pubmed] PHST- 2015/04/04 06:00 [medline] AID - 7668 [pii] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2014;18(15):2228-36.